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Abstract
Just like you would not buy a car without key information such as service history, you would not “buy” a clinical
trial report without key information such as concealment of allocation. Implementation of the updated CONSORT
2010 statement enables the reader to see exactly what was done in a trial, to whom and when. A fully
“CONSORTed” trial report does not necessarily mean the trial is a good one, but at least the reader can
make a judgement. Clear reporting is a pre-requisite for judgement of study quality. The CONSORT statement
evolves as empirical research moves on. CONSORT 2010 is even clearer than before and includes some new
items with a particular emphasis on selective reporting of outcomes. The challenge is for everyone to use it.
Introduction
I have bought many cars in my time. I search on the
Internet for specific models, and I make sure that they
have some key attributes such as a full service history,
road tax, certificate of roadworthiness and vehicle regis-
tration document before I spend time viewing them.
That does not mean to say that the “full service history”
is a good history, or that the registration document is a
genuine one, but at least the items are available for me
to make a judgement. Like me, I suspect that you would
not buy a car without such key information, so why
should it be any different when we “buy” a randomized
controlled trial report that does not mention certain
essential features such as a description of randomiza-
tion, allocation concealment, masking and whether all
those randomized were included in the analysis?
When I started off in clinical research some twenty
years ago, reporting key items in clinical trials was the
exception rather than the rule, especially in my own
field of dermatology [1]. But all that has changed or is
changing now [2] thanks to endeavours such as the
Consolidated Reporting of Trials (CONSORT) statement
that lists essential items to be included in any trial
report. I do not need to explain what the CONSORT
checklist is all about to readers of Trials, but I do need
to highlight the most recent update called CONSORT
2010 [3] published in Trials, and what it might mean
for you and me.
Discussion
Quality of reporting is not the same as trial quality
First, it is worth emphasising that the CONSORT 2010
statement is not an instrument to judge the quality of a
randomized control trial. As illustrated in Table 1, four
categories are formed when the two domains of trial
quality and trial reporting are combined into a four-
celled matrix. One is a clearly reported well-designed
trial that is useful for informing clinical practice. The
other is a clearly reported flawed study - not ideal, but
at least anyone can see the study shortcomings and
make a judgement about such a report. The remaining
two cells are the problems - the well-designed or flawed
study that is poorly reported. Both are of limited utility
because they lie in the grey zone of uncertainty. They
may be sparkling diamonds in a pile of rubble or just
rubble, and they may be difficult to distinguish from
each other - an observation that illustrates the primacy
of clear reporting.
Evolutionary not revolutionary
It is also important to realize that deciding on a minimum
list of essential items for clinical trial reports is a challen-
ging task, based on a combination of common sense
consensus and new evidence from empirical research.
Because opinions and research change with time, so too
the CONSORT statement evolves with time - initially in
2001 and now in 2010. General and specific changes to
CONSORT 2010 are explained fully in the statement, but
it is especially pleasing to note that the CONSORT Group
have resisted the temptation to simply add more items.
The Group have striven to make the interpretation of
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some older items even clearer e.g. by disaggregating items
that were composed of multiple items. New specific items
which excite me most include: a sub-item which asks
author to explain any changes to the methods after the
study starts; a better description of the interventions so
that they can be replicated; a more detailed description of
allocation concealment mechanisms rather than banal “get
out of jail free” statements like “allocation was concealed";
a clearer description of exactly what was meant by inten-
tion to treat; and a requirement that the interpretation of
the study findings should be consistent with the results.
The updated statement now also includes an item which
requires authors to say where the trial has been registered
and whether a protocol is publicly available - essential
aspects that allow referees and readers to check
on whether the authors have done what they said they
would do.
Throwing darts
Perhaps the most important change for me is the
emphasis on selective reporting of outcomes, which to
me is like throwing a dart then drawing a dartboard
around where it lands. There is now overwhelming evi-
dence that selective reporting of outcomes occurs [4]. I
see selective reporting of outcomes constantly in derma-
tology [5], especially when refereeing submitted articles.
Sometimes it is due to naivety, sometimes it is due to
financial conflicts of interest, and sometimes it is due to
a misguided desire to “save face” by trying to make
something positive out of a negative or inconclusive
result. Some call it avoidable waste [6]. I call it a distort-
ing the scientific record. Whilst some of the better der-
matology journals have striven to adopt CONSORT,
many of the remaining 240 specialist dermatology jour-
nals where “negative” trials end up (trials that are often
critical when assembling the totality of evidence in sys-
tematic reviews) have not, reinforcing the inverse
research reporting law - where the need for good trial
reporting is most, the quality of reporting is least. Help-
ing CONSORT 2010 to reach all the biomedical journals
is a challenge that needs to be taken up by all of us.
Influencing clinical research from trial design to clinic
CONSORT 2010 has the potential to play a critical role
in influencing clinical research and clinical practice in a
number of ways. First, I do believe that the statement has
and will continue to influence better trial design. In my
role of helping others to design clinical trials at our Not-
tingham Clinical Trials Unit, I find myself giving collea-
gues a hard time as a result of CONSORT to ensure that
the procedures for concealing allocation are robust e.g.
by ensuring that data on potentially eligible trial partici-
pants are entered irrevocably onto a database before
remote randomisation allocates the treatment group. I
also believe that CONSORT has led to better research
commissioning. The NIHR Health Technology Assess-
ment Board, which I now work for, insists that trial appli-
cations include a draft CONSORT flow chart of how
participants will be identified and allocated. When it
comes to trial publication, there is little doubt that CON-
SORT can improve the quality of reporting when
adhered to, although not all journals have the resources
to ensure such adherence. In my work as a systematic
reviewer, it is such a joy to come across a clearly reported
trial when abstracting data. Recent evidence has pointed
to the importance of how failure to account for reporting
outcome bias can lead to an exaggeration of effects and
different conclusions in systematic reviews [7], so the
emphasis on outcome reporting in CONSORT 2010 is
timely. Finally, as a practicing clinician, it is so much
easier to read trials that follow CONSORT in order to
see exactly what was done, by whom and when.
Conclusion
The benefits of CONSORT are manifest right from trial
conception to the application of evidence to patients in
the clinic. A trial that is “CONSORTED” gives a signal
to the reader that they can find what they want to find.
CONSORT 2010 is not a tool to catch out well inten-
tioned researchers with a straightjacket of prescriptive
reporting formats - it is simply an aid to ensure that a
trial report contains key information. Whether you are
buying a car or a trial report, you need essential infor-
mation to help you decide whether it is a good one.
CONSORT 2010 helps you to do that. Use CONSORT
2010 if you are a generator of research. Insist on it if
you are a user of research.
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Table 1 Trial reporting and study quality may be related but are not necessarily the same. All poorly reported trials
reside in the grey zone of uncertainty
Reporting quality Study quality
Good Flawed
Clear May be helpful for clinical practice. At least you can tell it is flawed and make a judgment on utility.
Poor A sparkling diamond – but how do you know? Difficult to distinguish from a good but poorly reported study.
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